reports
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
TLYS TILLYS
TCBI TEXAS CAPITAL BANCSHARES INC.
STAA STAAR SURGICAL CO.
PBF PBF ENERGY INC. CLASS A
OPK OPKO HEALTH INC.
LPSN LIVEPERSON INC.
CODI COMPASS DIVERSIFIED HOLDINGS
PESI PERMA-FIX ENVIRONMENTAL SERVICES INC.
RLMD RELMADA THERAPEUTICS
ADC AGREE REALTY CORPORATION
FBK FB FINANCIAL CORPORATION
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
DMLP DORCHESTER MINERALS L.P.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
CLF CLIFFS NATURAL RESOURCES INC.
JGH NUVEEN GLB HG
CMXC CELL MEDX
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
QNBC QNB CORP.
RCUS ARCUS BIOSCIENCES
AKTS AKOUSTIS TECHNOLOGIES INC
TLRY TILRAY
PAYS PAYSIGN INC
FBIO FABIEN CORP
ACET ADICET BIO INC
GRPN GROUPON INC.
VRDN VIRIDIAN THERAPEUTICS INC
AGL AGILON HEALTH
TBBK INC.
MPA THE BANCORP
SLDB INC.
COLB BLACKROCK MUNIYIELD PENNSYLVANIA FD
CRBP SOLID BIOSCIENCES INC
LSXMK COLUMBIA BANKING SYSTEM
INC.
CORBUS PHARMACEUTICALS HOLDINGS INC.
LIBERTY SIRIUSXM GROUP
- Jonathan Moreland
CWBC_x COMMUNITY WEST BANKSHARES
TLYS TILLYS
STAA STAAR SURGICAL CO.
PBF PBF ENERGY INC. CLASS A
OPK OPKO HEALTH INC.
LPSN LIVEPERSON INC.
FDX FEDEX CORPORATION
CPRX CATALYST PHARMACEUTICALS
CODI COMPASS DIVERSIFIED HOLDINGS
ASA ASA
PESI PERMA-FIX ENVIRONMENTAL SERVICES INC.
ADC AGREE REALTY CORPORATION
FIZZ NATIONAL BEVERAGE CORP.
FBK FB FINANCIAL CORPORATION
PKTX PROTOKINETIX INC
JGH NUVEEN GLB HG
CMXC CELL MEDX
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
CSBB C S B BANCORP OHIO
BWB BRIDGEWATER BANCSHARES
ZIVO ZIVO BIOSCIENCE
VRCA INC.
LOVE VERRICA PHARMACEUTICALS
TLRY LOVESAC
FBIO TILRAY
ACET FABIEN CORP
GRPN ADICET BIO INC
HPK GROUPON INC.
ATHA HIGHPEAK ENERGY INC (A)
VRDN ATHIRA PHARMA
AGL VIRIDIAN THERAPEUTICS INC
MPA AGILON HEALTH
SLDB INC.
BPRN BLACKROCK MUNIYIELD PENNSYLVANIA FD
MBRX SOLID BIOSCIENCES INC
LSXMA BANK OF PRINCETON
MOLECULIN BIOTECH INC
LIBERTY SIRIUSXM GROUP
- Jonathan Moreland
CWBC_x COMMUNITY WEST BANKSHARES
TLYS TILLYS
STAA STAAR SURGICAL CO.
OPK OPKO HEALTH INC.
OCUL OCULAR THERAPEUTIX
LPSN LIVEPERSON INC.
FLO FLOWERS FOODS INC.
FDX FEDEX CORPORATION
DLTR DOLLAR TREE INC.
CPRX CATALYST PHARMACEUTICALS
ASYS AMTECH SYSTEMS INC.
ASA ASA
PESI PERMA-FIX ENVIRONMENTAL SERVICES INC.
ADC AGREE REALTY CORPORATION
CYAN CYANOTECH
FIZZ NATIONAL BEVERAGE CORP.
PKTX PROTOKINETIX INC
CMXC CELL MEDX
CSBB C S B BANCORP OHIO
BWB BRIDGEWATER BANCSHARES
ZIVO ZIVO BIOSCIENCE
VRCA INC.
LOVE VERRICA PHARMACEUTICALS
TLRY LOVESAC
FBIO TILRAY
HPK FABIEN CORP
ATHA HIGHPEAK ENERGY INC (A)
HQI ATHIRA PHARMA
AGL HIREQUEST INC.
TCRX AGILON HEALTH
BCAB INC.
MPA FIRST EAGLE ALTERNATIVE CAPITAL BDC INC
SLDB BIOATLA INC
BPRN BLACKROCK MUNIYIELD PENNSYLVANIA FD
MBRX SOLID BIOSCIENCES INC
LSXMA BANK OF PRINCETON
MOLECULIN BIOTECH INC
LIBERTY SIRIUSXM GROUP
- Jonathan Moreland
- Jonathan Moreland
Cell MedX Corp. Files Premarket Notification (510K) with the US Food a...
Carson City, Nevada--(Newsfile Corp. - September 17, 2021) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that it has submitted a premarket notification (510K) to the U.S. Food and Drug Administration (FDA) for the eBalance® Home System and eBalance® Pro System.The eBalance® Pro System and eBalance® Home System, are microcurrent electrotherapy systems intended to administer a specific variety of thera...
Cell MedX Corp. Converts Debt to Shares, Closes Non-Brokered Private P...
Carson City, Nevada--(Newsfile Corp. - May 26, 2021) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general health and wellness, is pleased to announce that on May 25, 2021, the Company issued 2,484,500 common shares of the Company (the "Shares") on conversion of $496,900 the Company owed its debt holders under 6% demand notes payable and non-interest-bearing advances. In addition to issuance of the shares, the Debt holders agreed to forgive ...
Cell MedX Corp. Signs Extension Agreement with Think Ink Marketing
Carson City, Nevada--(Newsfile Corp. - September 24, 2020) - Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general health and wellness, announced today that it has signed an extension agreement with Think Ink Marketing Data & Email Services, Inc. ("Think Ink") to provide public relations services in an effort to increase public awareness of the Company and its products, services and securities. The agreement is for twelve month...
Cell MedX Corp.'s eBalance Pro System Receives Class II Medical Device...
Carson City, Nevada--(Newsfile Corp. - September 1, 2020) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), a bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general health and wellness, is happy to announce that in August 2020, Health Canada granted Cell MedX (Canada) Corp., the Company's wholly-owned subsidiary, a Class II Medical Device License for its innovative eBalance Pro System. The License #105044 was issued in accordance with the Medical Device Regulations, Section 36. eBalance P...
Cell MedX Corp. Closes Non-Brokered Private Placement Financing
Carson City, Nevada--(Newsfile Corp. - August 4, 2020) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), a bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general health and wellness, is pleased to announce that on July 30, 2020, the Company closed its non-brokered private placement offering (the "Offering") at a price of $0.25 per unit (the "Unit"), by issuing 988,000 Units for total gross proceeds of $247,000. Each Unit sold under the Offering consisted of one common share of the Company and...
Cell MedX Corp.'s eBalance Home System Receives Class II Medical Devic...
Carson City, Nevada--(Newsfile Corp. - July 22, 2020) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general health and wellness, is happy to announce that on July 17, 2020, Health Canada granted Cell MedX (Canada) Corp., the Company's wholly-owned subsidiary, a Class II Medical Device License for its innovative eBalance Home System. The License #104925 was issued in accordance with the Medical Device Regulations, Section 36. eBalance Hom...
Cell MedX Corp. Files Two Applications for Class II Medical Device Lic...
Carson City, Nevada--(Newsfile Corp. - July 7, 2020) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that the Company has filed an application for a Class II Medical Device License for the eBalance Pro System and the eBalance Home System with Health Canada. The applications consisted of the Device License Application and Fee Forms, Labelling and Quality System Requirements: Quality System Certificate for ISO ...
Cell MedX Corp. Receives Quality Management System ISO 13485:2016 MDSA...
Carson City, Nevada--(Newsfile Corp. - June 9, 2020) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that the Company received a Quality Management System - ISO 13485:2016 certificate #MDSAP 716274 for design, development, and manufacture of microcurrent therapeutic devices, specifically the Company's eBalance® device. As further announced in the Company's news release published on April 7, 2020, in February 2...
Cell MedX Corp. Announces a Non-Brokered Private Placement Financing
Carson City, Nevada--(Newsfile Corp. - April 17, 2020) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that the Company has arranged a non-brokered private placement offering (the "Offering") set at a price of $0.25 per Unit for up to 1,000,000 Units for total gross proceeds of $250,000. Each Unit sold under the Offering will consist of one common share of the Company and one share purchase warrant (the "Warran...
Cell MedX Corp. Receives Quality Management System ISO 13485:2016 Cert...
Carson City, Nevada--(Newsfile Corp. - April 7, 2020) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that the Company received a Quality Management System - ISO 13485:2016 certification for the Company's eBalance® device (the "Device").At the end of February 2020 BSI Group Canada Inc. completed a Stage 2 audit on the Company. The audit objective was to conduct a Medical Device Singl...
Cell MedX Corp. Reacquires World Wide Exclusivity Rights for the eBala...
Carson City, Nevada--(Newsfile Corp. - January 30, 2020) - Cell MedX Corp. (OTCQB: CMXC) (MUN: 9CX) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that the Company has repurchased the worldwide exclusive direct rights for distribution of its eBalance® devices.Cell MedX identified two distribution market channels for sales of the eBalance® device, individual rights for home based use ("Direct Rights") and wholesale rights for use by cl...
Cell MedX Corp. Engages Dr. Peter Eppinga as Lead Investigator in the ...
Carson City, Nevada--(Newsfile Corp. - December 12, 2019) - Cell MedX Corp. (OTCQB: CMXC) (MUN: 9CX) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that the Company has recruited Dr. Peter Eppinga, a family practice physician (MD, CCFP) licensed in the province of British Columbia, Canada, as the lead investigator in the eBalance® R&D Experience Study (the "Study"). For additional information please refer to the news release the Comp...
Cell MedX Corp. Receives eBalance Trademark
Carson City, Nevada--(Newsfile Corp. - October 17, 2019) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that the European Union has approved the Company's eBalance trademark application, and issued certificate of registration number 017997155 registering the trademark eBalance in the name of the Company. The eBalance trademark was also recently registered in the U.K., bearing the registration number UK...
Cell MedX Corp. Provides Corporate Update
Carson City, Nevada--(Newsfile Corp. - September 12, 2019) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is excited to provide its shareholders with a corporate update. Certifications In Fiscal year 2019 the Company received a Certificate of Conformity, from LabTest Certification Inc., for the ebalance Pro device (the "Device"). The certification tests performed qualified the Device as a Class A and Class B device. Class A...
Cell MedX Corp. Issues Clarifying Release Regarding the Bull Report Ar...
Carson City, Nevada--(Newsfile Corp. - September 10, 2019) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a biotech company focused on the discovery, development and commercialization of therapeutic and nontherapeutic products that promote general wellness, is issuing this news release to clarify that the article dated July 24, 2019 appearing in the TheBullReport.com was prepared on behalf of the Company.As previously announced, the Company has engaged the services of Think Ink Marketing Data & Email Services, Inc. ("Think Ink") to develop an investor outreach program. As par...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.